Tumor adoptive immunotherapy 肿瘤过继疗法
This research is going to studying the anti-tumor activity of tumor antigen induced cord blood cells based on the definition of adoptive immunotherapy.
本研究正是从过继性免疫细胞治疗的概念出发，探讨肿瘤抗原诱导的脐血细胞的抗肿瘤效应。
CONCLUSION: CIK cells have strong proliferative ability and higher cytotoxicity to tumor cells in vitro, which could be used as a potential anti-tumor adoptive immunotherapy in clinic.
结论：CIK细胞在体外扩增能力强，对肿瘤细胞的杀伤活性高，有望成为新一代抗肿瘤过继免疫细胞制剂而应用于临床。
The cell used in adoptive immunotherapy must have strong cytotoxic and proliferative ability, so CIK cell is thought of the new generation anti-tumor adoptive immunity treatment.
用于过继免疫治疗的活性细胞必须具有较强的细胞活性和增殖力，CIK细胞被认为是新一代抗肿瘤过继细胞免疫治疗的首选方案。
应用推荐